Scorr-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Alfa-2B

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 13, 2020

            Details:

            The study investigated the use of interferon alpha-2b on 77 patients with moderate cases of COVID-19 and found that the interferon alpha-2b drug significantly accelerated clearance of the virus from the airways of patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Interferon Alfa-2B

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2020

            Details:

            Results from a recent trial suggests a significantly shorter time to viral clearance for patients treated with interferon alpha 2b (IFN?2b) compared to the group who received arbidol alone.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AntiCovir

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: BetterLife Pharma

            Deal Size: $20.0 million Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement May 07, 2020

            Details:

            BetterLife Pharma has been worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell AntiCovir, a COVID-19 treatment, from Altum Pharmaceuticals Inc.